132 / 1498
•
R-chemo SoC in most B-cell lymphoma including
DLBCL and low-grade lymphoma
•
MoAb-based maintenance established in low grades
and cHL; role of maintenance in DLBCL unclear
•
Anti-PD1 moabs extremely promising, mainly in HL
•
Immunotherapy might at least in part replace chemo-
and radiotherapy in the future
Immunotherapy of malignant lymphoma